A multinational, multicenter, randomized, Phase III, double blind, parallel group, placebo controlled study in subjects with Relapsing forms of Multiple Sclerosis (RMS) to assess the efficacy, safety and tolerability of GA Depot, a long acting IM injection of glatiramer acetate, administered once every four weeks

Mapi Pharma Ltd.0 个研究点目标入组 960 人开始时间: 2019年10月2日最近更新: 2023年7月18日

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Mapi Pharma Ltd.
入组人数: 960

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. Adult subjects between 18-55 years of age, inclusive.
•2. Subjects able to provide signed written informed consent.
•3. Subjects must be willing and able to comply with the protocol requirements for the duration of the study.
•4. MS diagnosis fulfilling the 2017 McDonald Criteria.
•5. Subjects should be ambulatory with an EDSS score of 0-5.5 at screening and baseline visits. EDSS score will be determined by a separate, blinded trained EDSS rater.
•6. Subjects should be relapse free and neurologically stable from one month before screening visit and from screening visit to baseline visit.
•7. No systemic corticosteroid treatment or ACTH within one month prior to screening visit.
•8. Subjects must have experienced at least one of the following:
•i. One documented relapse in the 12 months prior to screening.
•ii. Two documented relapses in the 24 months prior to screening.
•iii. One documented relapse between 12 and 24 months prior to screening, with at least one documented T1-Gd enhancing lesion in MRI performed within 0-12 months before screening.
•9. Women capable of child bearing must have a negative urine pregnancy test at screening visit and use an adequate contraceptive method throughout the study.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 960
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

排除标准

•1. Use of experimental / investigational drug, and / or participation in drug clinical studies within the 6 months prior to screening.
•2. Any off-label drug use for MS treatment such as high dose simvastatin and biotin within 6 months prior to screening.
•3. Previous use of immunosuppressant including Mitoxantrone, Alemtuzumab, cladribine or any other cytotoxic agent.
•4. Previous use of natalizumab or any anti-B cell agent within 9 months prior to screening.
•5. Previous use of Fingolimod or Dimethyl Fumarate within 2 months prior to screening. Subjects will be excluded if they do not have a lymphocyte count of above 1,000/mm3 at screening.
•6. Previous use of Teriflunomide within 12 months if no accelerated elimination procedure was used.
•7. Previous treatment with immunomodulators (including IFNß 1a and 1b, and IV Immunoglobulin (IVIg) within 2 months prior to screening.
•8. Previous use of GA or any other glatiramoid.
•9. Chronic (more than 30 consecutive days) systemic (IV, PO or IM) corticosteroid treatment within 6 months prior to screening visit.
•10. Previous total body irradiation or total lymphoid irradiation.
•11. Previous stem-cell treatment, autologous bone marrow transplantation or allogeneic bone marrow transplantation.
•12. Subjects with a clinically significant or unstable medical, psychiatric, or surgical conditions that would preclude safe and complete study participation, as determined by medical history, physical exams, ECG and/or abnormal laboratory tests. Such conditions may include hepatic, renal or metabolic diseases, systemic disease, acute infection, current malignancy, or recent history (5 years) of malignancy, major psychiatric disorder, history of drug and/or alcohol abuse and allergies that could be detrimental according to the investigator's judgment.
•13. Subjects who have >10 T1-Gd enhancing lesions at screening.
•14. A known history of sensitivity to Gadolinium.
•15. Inability to successfully undergo MRI scanning.
•16. Pregnant or breast-feeding women.
•17. Abnormal renal function (serum creatinine 1.5xULN or creatinine clearance <60 ml/min).
•18. Abnormal liver function (transaminases >2xULN).
•19. History of any anaphylactic reaction and/or serious allergic reaction following a vaccination, a proven hypersensitivity to any component of the study article (e.g., GA, Polyglactin, PVA).
•20. A history of positive VDRL or positive testing for HIV, hepatitis, or tuberculosis.
•21. Known or suspected history of drug or alcohol abuse.
•22. Subjects diagnosed with any systemic autoimmune disease (other than MS) that may impact the CNS with MS like lesions such as Sarcoidosis, Sjögren's syndrome, Systemic Lupus Erythematosus (SLE), Lyme disease, Antiphospholipid antibodies (APLA) syndrome, etc. Subjects with stable local/organ autoimmune disease such as psoriasis, cutaneous lupus erythematosus, thyroiditis (Hashimoto's, Grave's) etc. may be considered eligible upon the investigator's discretion.
•23. Any CNS disorder other than MS that may jeopardize the subject's participation in the study.
•24. Subjects with uncontrolled diabetes.
•25. Subjects with clotting disorders or receiving treatment with anticoagulants .

研究者

发起方

Mapi Pharma Ltd.

相似试验

进行中（未招募）

1 期

A multinational, multicenter, randomized, Phase III, double blind, parallel group, placebo controlled study in subjects with Relapsing forms of Multiple Sclerosis (RMS) to assess the efficacy, safety and tolerability of GA Depot, a long acting IM injection of glatiramer acetate, administered once every four weeks

EUCTR2018-000284-93-BGMapi Pharma Ltd.1,000

进行中（未招募）

1 期

EUCTR2007-001105-13-GBF. Hoffmann-La Roche Ltd, Pharmaceuticals Division, PDR417

进行中（未招募）

不适用

EUCTR2007-001105-13-ATF. Hoffmann-La Roche Ltd400

进行中（未招募）

不适用

A randomised, multicenter, multinational Phase II study on trastuzumab plus docetaxel versus trastuzumab plus docetaxel plus pertuzumab versus trastuzumab plus pertuzumab in patients with locally advanced, inflammatory or early stage HER2 positive breast cancer.ocally advanced, inflammatory or early stage HER2 positive breast cancer.MedDRA version: 14.1Level: LLTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10006200Term: Breast cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10006201Term: Breast cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10021974Term: Inflammatory breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2007-001105-13-ITHoffman - La Roche400

进行中（未招募）

不适用

A randomised, multicenter, multinational Phase II study on trastuzumab plus docetaxel versus trastuzumab plus docetaxel plus pertuzumab versus trastuzumab plus pertuzumab versus pertuzumab and docetaxel in patients with locally advanced, inflammatory or early stage HER2 positive breast cancer.ocally advanced, inflammatory or early stage HER2 positive breast cancer.MedDRA version: 14.1Level: PTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10006200Term: Breast cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10006201Term: Breast cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10021974Term: Inflammatory breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2007-001105-13-PLF. Hoffmann-La Roche Ltd400